After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers ...
Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results